F Nelli1, A Virtuoso2, J R Giron Berrios2, D Giannarelli3, A Fabbri2, E Marrucci2, E M Ruggeri2. 1. Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Strada Sammartinese Snc, 01100, Viterbo, Italy. fabrizio.nelli@asl.vt.it. 2. Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Strada Sammartinese Snc, 01100, Viterbo, Italy. 3. Biostatistics Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Abstract
BACKGROUND: Immunosuppressive dosing of corticosteroids at the start of treatment impairs immune checkpoint inhibitor (ICI) efficacy in advanced non-small cell lung cancer (NSCLC). Previous cumulative dose and intake modality of corticosteroids may result in different levels of immunosuppression. We sought to determine whether these aspects could predict disease control and survival in NSCLC patients receiving ICIs. METHODS: We conducted a retrospective single-center study, including patients treated with ICI as second-line therapy at our institution between July 2015 and February 2021. A prednisone equivalent threshold of 700 mg defined low (LCD) or high (HCD) cumulative dosing during the 90 days before starting ICIs. At least one 5-day course of ≥ 10 mg prednisone equivalent determined whether the intake was pulse (PCD, ≤ 5 days) or continuous (CCD, > 5 days). RESULTS: We included 113 consecutive patients. Durable control benefit and no clinical benefit (NCB) were reported in 53 (47%) and 60 (53%) of the cases, respectively. ECOG PS 1-2, negative PD-L1 expression, HCD, and CCD were significantly related to NCB in multivariate analysis. The median PFS was 4.6 months (95%CI: 3.9-6.3) and median OS was 6.9 months (95% CI: 6.0-8.9) after a median follow-up time of 43.5 months (95% CI: 32.6-54.4). Multivariate analysis of survival confirmed ECOG PS 1-2 (p = 0.005), negative PD-L1 expression (p = 0.002), and CCD (p = 0.001) significantly correlated with an increased risk of mortality. CONCLUSIONS: These findings imply that immunosuppressive corticosteroid dosing before ICIs, even of short duration, might affect survival. The constraints of this study and lack of reliable comparisons suggest a hypothesis-generating value of these results.
BACKGROUND: Immunosuppressive dosing of corticosteroids at the start of treatment impairs immune checkpoint inhibitor (ICI) efficacy in advanced non-small cell lung cancer (NSCLC). Previous cumulative dose and intake modality of corticosteroids may result in different levels of immunosuppression. We sought to determine whether these aspects could predict disease control and survival in NSCLC patients receiving ICIs. METHODS: We conducted a retrospective single-center study, including patients treated with ICI as second-line therapy at our institution between July 2015 and February 2021. A prednisone equivalent threshold of 700 mg defined low (LCD) or high (HCD) cumulative dosing during the 90 days before starting ICIs. At least one 5-day course of ≥ 10 mg prednisone equivalent determined whether the intake was pulse (PCD, ≤ 5 days) or continuous (CCD, > 5 days). RESULTS: We included 113 consecutive patients. Durable control benefit and no clinical benefit (NCB) were reported in 53 (47%) and 60 (53%) of the cases, respectively. ECOG PS 1-2, negative PD-L1 expression, HCD, and CCD were significantly related to NCB in multivariate analysis. The median PFS was 4.6 months (95%CI: 3.9-6.3) and median OS was 6.9 months (95% CI: 6.0-8.9) after a median follow-up time of 43.5 months (95% CI: 32.6-54.4). Multivariate analysis of survival confirmed ECOG PS 1-2 (p = 0.005), negative PD-L1 expression (p = 0.002), and CCD (p = 0.001) significantly correlated with an increased risk of mortality. CONCLUSIONS: These findings imply that immunosuppressive corticosteroid dosing before ICIs, even of short duration, might affect survival. The constraints of this study and lack of reliable comparisons suggest a hypothesis-generating value of these results.
Authors: Kathryn C Arbour; Laura Mezquita; Niamh Long; Hira Rizvi; Edouard Auclin; Andy Ni; Gala Martínez-Bernal; Roberto Ferrara; W Victoria Lai; Lizza E L Hendriks; Joshua K Sabari; Caroline Caramella; Andrew J Plodkowski; Darragh Halpenny; Jamie E Chaft; David Planchard; Gregory J Riely; Benjamin Besse; Matthew D Hellmann Journal: J Clin Oncol Date: 2018-08-20 Impact factor: 44.544
Authors: Nasser H Hanna; Andrew G Robinson; Sarah Temin; Sherman Baker; Julie R Brahmer; Peter M Ellis; Laurie E Gaspar; Rami Y Haddad; Paul J Hesketh; Dharamvir Jain; Ishmael Jaiyesimi; David H Johnson; Natasha B Leighl; Pamela R Moffitt; Tanyanika Phillips; Gregory J Riely; Rafael Rosell; Joan H Schiller; Bryan J Schneider; Navneet Singh; David R Spigel; Joan Tashbar; Gregory Masters Journal: J Clin Oncol Date: 2021-02-16 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Giovanni Fucà; Giulia Galli; Marta Poggi; Giuseppe Lo Russo; Claudia Proto; Martina Imbimbo; Roberto Ferrara; Nicoletta Zilembo; Monica Ganzinelli; Antonio Sica; Valter Torri; Mario Paolo Colombo; Claudio Vernieri; Andrea Balsari; Filippo de Braud; Marina Chiara Garassino; Diego Signorelli Journal: ESMO Open Date: 2019-02-27